Visen Pharmaceuticals IPO Launches on Hong Kong Stock Exchange Amid Growth in Endocrine Therapies
China-based Visen Pharmaceuticals, a joint venture between Denmark-headquartered Ascendis Pharma and Vivo Capital, has successfully...
Ascendis Pharma
Ascendis Pharma’s TransCon hGH sBLA for Adult GHD Accepted by FDA
Denmark-based Ascendis Pharma A/S (NASDAQ: ASND) has announced that the US Food and Drug Administration...
Novo Nordisk Secures Global Licensing Agreement with Ascendis Pharma for TransCon Technology
Denmark-based healthcare giant Novo Nordisk (NYSE: NVO; CPH: NOVO-B) has entered into a licensing agreement...
Ascendis Pharma’s Hypoparathyroidism Therapy Yorvipath Wins FDA Nod, Fills Market Gap
This week, the U.S. Food and Drug Administration (FDA) granted market approval to Ascendis Pharma...
Visen Pharmaceuticals’ TransCon hGH Accepted for Review by China’s NMPA
Visen Pharmaceuticals, a joint venture between Denmark-based Ascendis Pharma and Chinese healthcare-focused investment firm Vivo...
WuXi Biologics Partners with Visen Pharmaceuticals for Lonapegsomatropin Manufacturing
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has entered into...
Visen Pharmaceuticals Reports Positive Phase II Results for TransCon CNP in Achondroplasia
Visen Pharmaceuticals, a joint venture between Denmark-based Ascendis Pharma A/S (NASDAQ: ASND) and Chinese healthcare...
Visen Pharmaceuticals Files for Hong Kong IPO with Focus on Growth Hormone
Visen Pharmaceuticals, a China-based joint venture between Denmark-headquartered Ascendis Pharma and Chinese healthcare-focused investment firm...